Valirx Regulatory News (VAL)



Regulatory News for Valirx (VAL)


Share Price: 0.46Bid: 0.44Ask: 0.48Change: 0.00 (0.00%)No Movement on Valirx
Spread: 0.04Spread as %: 9.09%Open: 0.465High: 0.4636Low: 0.436Yesterday’s Close: 0.46





Holding(s) in Company

Thu, 24th Nov 2011 07:00

RNS Number : 6613S
ValiRx PLC
24 November 2011
 

?

 




TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi



1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
ii

VALIRX PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached


An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments


An event changing the breakdown of voting rights


Other (please specify):



3. Full name of person(s) subject to the
notification obligation:
iii

Peter James Crowson

4. Full name of shareholder(s)
 (if different from 3.):iv


5. Date of the transaction and date on
which the threshold is crossed or
reached:
v

22nd November 2011

6. Date on which issuer notified:

22nd November 2011

7. Threshold(s) that is/are crossed or
reached:
vi, vii

5%



 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00B23N9136

50,866,203

50,866,203

52,854,868

52,854,868


5%




B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date
xiii

Exercise/
Conversion Period
xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights







C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period
xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 





 

 

Nominal

Delta




Total (A+B+C)

Number of voting rights

Percentage of voting rights

52,854,868

5%



 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi

 

 


Proxy Voting:

10. Name of the proxy holder:


11. Number of voting rights proxy holder will cease
to hold:


12. Date on which proxy holder will cease to hold
voting rights:




13. Additional information:



14. Contact name:

Peter Crowson

15. Contact telephone number:

07766 461230



 

Note: Annex should only be submitted to the FSA not the issuer

Annex: Notification of major interests in share


A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 


Contact address

(registered office for legal entities)

 


Phone number & email

 


Other useful information

(at least legal representative for legal persons)

 




B: Identity of the notifier, if applicable

Full name

 


Contact address

 


Phone number & email

 


Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)



C: Additional information


For notes on how to complete form TR-1 please see the FSA website.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUORNRASAAUAA


Related Shares: Valirx (VAL).




DateSourceHeadlineCategory
25-Apr-13 07:00RNSNew Patent GrantedCompany Announcement - General
22-Apr-13 11:52RNSResult of AGMResults and Trading Reports
02-Apr-13 07:00RNS-RUpdate on Developmental and Clinical ActivityCompany Announcement - General
28-Mar-13 07:01RNSFinal ResultsResults and Trading Reports
21-Feb-13 07:00RNS-RRe Commercial Development UpdateCompany Announcement - General
23-Jan-13 07:00RNSAppointment of Medical Monitoring OfficerCompany Announcement - General
31-Dec-12 07:00RNSTotal Voting RightsHolding(s) in Company
22-Nov-12 07:00RNSRe: UpdateCompany Announcement - General
19-Nov-12 12:19RNSResult of General MeetingResults and Trading Reports
01-Nov-12 13:49RNSPlacing and Notice of General MeetingCompany Announcement - General
11-Oct-12 07:00RNSre: UK Distribution AgreementCompany Announcement - General
20-Sep-12 07:00RNSHalf Yearly ReportResults and Trading Reports
06-Sep-12 07:00RNSVAL201 Update re: Breast Cancer StudyCompany Announcement - General
02-Aug-12 07:00RNSRe: GeneICE and Biomarkers Development UpdateCompany Announcement - General
29-May-12 11:07RNSResult of AGMResults and Trading Reports
29-May-12 07:00RNSUpdate re: Late Pre-clinical Study of VAL201Company Announcement - General
15-May-12 07:00RNSNew US Patent GrantCompany Announcement - General
27-Apr-12 07:00RNSFinal ResultsResults and Trading Reports
02-Apr-12 12:17RNSDirector/PDMR ShareholdingDirectors' Dealings
02-Apr-12 07:00RNSPlacing of GBP 900,000 and Director's DealingCompany Announcement - General
29-Mar-12 07:00RNSRe AgreementCompany Announcement - General
08-Mar-12 07:00RNSPeer Review Findings Published re VAL201Company Announcement - General
14-Feb-12 07:00RNSEstablishment of Scientific & Advisory BoardCompany Announcement - General
02-Feb-12 07:00RNSNew European Patent GrantCompany Announcement - General
31-Jan-12 10:14RNSTotal Voting RightsHolding(s) in Company
05-Jan-12 07:00RNSAcquisitionMergers, Acquisitions and Disposals
15-Dec-11 07:00RNSNew Patent Grant for GeneICE & VAL101 UpdateCompany Announcement - General
09-Dec-11 16:23RNSRe Volition - Allotment of SharesCompany Announcement - General
24-Nov-11 07:00RNSHolding(s) in CompanyHolding(s) in Company
03-Nov-11 07:00RNSNew Patent FilingCompany Announcement - General


Regulatory news is displayed end of day, each day at 19:00.
Sign up for Live Prices





Datafeed and UK data supplied by NETbuilder and Interactive Data. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.